Skip to main content
. 2012 Nov 25;5(1):149–166. doi: 10.1002/emmm.201201378

Figure 9. Combination of IKKβ/NF-κB inhibitor (BMS345541) and AURKA inhibitor (MLN8237) does not produce a synergistic inhibitory effect on tumour growth.

Figure 9

  • A. Patient tumour tissues (V32) were implanted subcutaneously into nude mice. After 1 week, tumour-bearing mice received daily oral doses of BMS-345541 (100 mg/kg) or MLN8237 (30 mg/kg) or both. Mean tumour volumes ± SEM are shown (n = 5).
  • B. H&E staining of the V32 patient tumours from mice treated with vehicle, BMS345541, MLN8237, or both BMS345541 and MLN8237.
  • C,D. Hs294T melanoma cells were injected subcutaneously into nude mice (2 × 106 cells per mouse). After 1 week, tumour-bearing mice received daily oral doses of BMS-345541 [100 mg/kg (C) or 75 mg/kg (D)] or MLN8237 (30 mg/kg) or 30 mg/kg MLN8237 combined with 100 mg/kg BMS345541 (C) or 75 mg/kg BMS345541 (D). Mean tumour volumes ± SEM are shown. (n = 5).
  • E. Diagrammatic representation of the proposed model of MLN8237-induced senescence and senescence surveillance by immune cells.